NCT02220244 - Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis | Biotech Hunter

Enrollment

105

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

December 31, 2015

Study Completion Date

January 31, 2018

Conditions

Multiple Sclerosis

Interventions

DRUG

MD1003 100mg capsule

Trial Locations (20)

13000

Hopital de la Timone, Marseille

14000

Hopital de la cote de Nacre, Caen

21000

Hopital general du Bocage, Dijon

31000

Hopital Purpan, Toulouse

33000

Hopital Pellegrin, Bordeaux

34000

Hopital Gui de Chauliac, Montpellier

35000

Hopital Pontchaillou, Rennes

44000

Hopital Nord Laennec, Nantes

51000

Hopital Maison Blanche, Reims

54000

Hopital Central, Nancy

59000

CHRU de Lille, Lille

63000

Hopital Gabriel Montpied, Clermont-Ferrand

67000

Hopital de Hautepierre, Strasbourg

69000

Hopital Pierre Wertheimer, Lyon

75012

Centre hospitalier national d'ophtalmologie des Quinze Vingts, Paris

75013

Groupe hospitalier la Pitie-Salpetriere, Paris

75019

Fondation Rothschild, Paris

78300

Centre hospitalier Intercommunal Poissy/Saint-Germain-en-Laye, Poissy

06000

Hopital Pasteur, Nice

WC1N 3BG

UCL Institute of Neurology, London